Soluble Urokinase Receptor and Chronic Kidney Disease.
1. Motzer RJ, Sharma P, McDermott DF, et al. CheckMate 025 phase III trial: outcomes by key baseline factors and prior therapy for nivolumab (NIVO) vs everolimus (EVE) in advanced renal cell carcinoma (RCC) Presented at the 2016 Genitourinary Cancers Symposium, San Francisco, January 7 9, 2016. abstract. 2. Opdivo (nivolumab) injection (prescribing information) Princeton, NJ: Bristol Myers Squibb, November 2015 (http: packageinserts.bms.com/pi/pi_opdivo.pdf) 3. Haider MT, Hunter KD, Robinson SP, et al. Rapid modification of the bone microenvironment following short term treatment with cabozantinib in vivo. Bone 2015; 81: 581 92. 4. McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, Choueiri TK. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol 2014; 66: 502 9. 5. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma. N Engl J Med 2015; 373: 1814 23. DOI: 10.1056/NEJMc1515613
The New England journal of medicine